News & Updates

Treatment with pyrotinib in combination with trastuzumab and docetaxel (tras/doc) results in longer progression-free survival (PFS) than placebo combined with tras/doc in patients with untreated HER2-positive metastatic breast cancer, a study has shown. In addition, the safely profile of tras/doc plus pyrotinib is manageable.

Use of the lung immune prognostic index (LIPI) score can help predict the efficacy of combination therapy of programmed cell death (PD)-1/PD-ligand 1 (PD-L1) blockade and chemotherapy (CT) in patients with advanced nonsmall cell lung cancer (NSCLC), suggests a study.

Patients with nonsmall cell lung cancer (NSCLC) who have been treated with neoadjuvant immunotherapy show greater response than those treated with neoadjuvant chemotherapy (CT), as shown in a study. Treatment-related adverse events (TRAEs) are similar between the two groups.

In the phase III MARIPOSA trial, the amivantamab-lazertinib cocktail outdid osimertinib as first-line (1L) treatment for EGFR-mutated, advanced non-small cell lung cancer (NSCLC).

Treatment with placebo is successful in patients with open-angle glaucoma or ocular hypertension, achieving lower intraocular pressure (IOP), compared with untreated control participants, reports a recent study.

Management of most adults with COVID-19, particularly those with mild-to-moderate disease, is increasingly occurring in the outpatient setting due to the availability of effective treatment options. 

Rosuvastatin is as effective as atorvastatin for the composite outcome of all-cause death, myocardial infarction (MI), stroke, or any coronary revascularization at 3 years in adults with coronary artery disease (CAD), according to the secondary analysis of the LODESTAR trial.